{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T14:58:39Z","timestamp":1764687519969},"reference-count":33,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2008,5,1]],"date-time":"2008-05-01T00:00:00Z","timestamp":1209600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2008,5]]},"DOI":"10.1016\/j.ejphar.2007.11.056","type":"journal-article","created":{"date-parts":[[2007,12,4]],"date-time":"2007-12-04T09:17:50Z","timestamp":1196759870000},"page":"234-243","source":"Crossref","is-referenced-by-count":24,"title":["Anti-thrombotic and vascular effects of AR246686, a novel 5-HT2A receptor antagonist"],"prefix":"10.1016","volume":"586","author":[{"given":"John W.","family":"Adams","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danny","family":"Ortuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunqing","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Thomsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy G.","family":"Richman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Dosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley R.","family":"Teegarden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hussien","family":"Al-Shamma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominic P.","family":"Behan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel T.","family":"Connolly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2007.11.056_bib1","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1161\/01.CIR.73.3.572","article-title":"Serotonin as a mediator of cyclic flow variations in stenosed canine coronary arteries","volume":"73","author":"Ashton","year":"1986","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2007.11.056_bib2","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1055\/s-0037-1615615","article-title":"Antiplatelet and antithrombotic activity of SL65.0472, a mixed 5-HT1B\/5-HT2A receptor antagonist","volume":"85","author":"Berry","year":"2001","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ejphar.2007.11.056_bib3","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction","volume":"22","author":"Cheng","year":"1973","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2007.11.056_bib4","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1517\/14740338.5.6.815","article-title":"The safety and efficacy of aspirin and clopidogrel as a combination treatment in patients with coronary heart disease","volume":"5","author":"Cooke","year":"2006","journal-title":"Expert. Opin. Drug Saf."},{"key":"10.1016\/j.ejphar.2007.11.056_bib5","first-page":"228","article-title":"5-hydroxytryptamine and platelet aggregation","volume":"42","author":"De Clerck","year":"1983","journal-title":"Fed. Proc."},{"key":"10.1016\/j.ejphar.2007.11.056_bib6","first-page":"S87","article-title":"Amplification mechanisms in platelet activation and arterial thrombosis","volume":"8","author":"De Clerck","year":"1990","journal-title":"J. Hypertens. Suppl."},{"key":"10.1016\/j.ejphar.2007.11.056_bib7","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1124\/jpet.103.063610","volume":"309","author":"Dogne","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2007.11.056_bib8","first-page":"39P","article-title":"Proceedings: platelet release reaction induced by 5-hydroxytryptamine","volume":"240","author":"Drummond","year":"1974","journal-title":"J. Physiol."},{"key":"10.1016\/j.ejphar.2007.11.056_bib9","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1172\/JCI12242","article-title":"Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs","volume":"107","author":"Foster","year":"2001","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejphar.2007.11.056_bib10","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3109\/07853890008998827","article-title":"Serotonin and the heart","volume":"32","author":"Frishman","year":"2000","journal-title":"Ann. Med."},{"key":"10.1016\/j.ejphar.2007.11.056_bib11","doi-asserted-by":"crossref","first-page":"E16","DOI":"10.1067\/mhj.2003.176","article-title":"Sarpogrelate treatment reduces restenosis after coronary stenting","volume":"145","author":"Fujita","year":"2003","journal-title":"Am. Heart. J."},{"key":"10.1016\/j.ejphar.2007.11.056_bib12","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/PL00005318","article-title":"Differences in agonist-independent activity of 5-Ht2A and 5-HT2c receptors revealed by heterologous expression","volume":"359","author":"Grotewiel","year":"1999","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.ejphar.2007.11.056_bib13","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1055\/s-0038-1651592","article-title":"Antithrombotic activity of SR 46349, a novel, potent and selective 5-HT2 receptor antagonist","volume":"69","author":"Herbert","year":"1993","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ejphar.2007.11.056_bib14","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.pharmthera.2005.12.004","article-title":"5-hydroxytryptamine receptors in the human cardiovascular system","volume":"111","author":"Kaumann","year":"2006","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2007.11.056_bib15","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0014-2999(01)01432-7","article-title":"Antithrombotic activity of AT-1015, a potent 5-HT(2A) receptor antagonist, in rat arterial thrombosis model and its effect on bleeding time","volume":"433","author":"Kihara","year":"2001","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2007.11.056_bib16","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2174\/1568026023393796","article-title":"Molecular biology of serotonin receptors structure and function at the molecular level","volume":"2","author":"Kroeze","year":"2002","journal-title":"Curr. Top Med. Chem."},{"key":"10.1016\/j.ejphar.2007.11.056_bib17","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/0049-3848(90)90106-M","article-title":"Rat model of arterial thrombosis induced by ferric chloride","volume":"60","author":"Kurz","year":"1990","journal-title":"Thromb. Res."},{"key":"10.1016\/j.ejphar.2007.11.056_bib18","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1161\/01.ATV.0000092127.16125.E6","article-title":"Differential involvement of the P2Y1 and P2Y12 receptors in platelet procoagulant activity","volume":"23","author":"Leon","year":"2003","journal-title":"Arterioscler.Thromb. Vasc.Biol."},{"key":"10.1016\/j.ejphar.2007.11.056_bib19","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2174\/1568007043482598","article-title":"5-HT2 receptors","volume":"3","author":"Leysen","year":"2004","journal-title":"Curr. Drug Targets CNS. Neurol. Disord."},{"key":"10.1016\/j.ejphar.2007.11.056_bib20","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/00001721-199711000-00006","article-title":"Effects of serotonin on platelet activation in whole blood","volume":"8","author":"Li","year":"1997","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"10.1016\/j.ejphar.2007.11.056_bib21","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1254\/jphs.FP0060610","article-title":"Inverse agonist activity of sarpogrelate, a selective 5-HT2A-receptor antagonist, at the constitutively active human 5-HT2A receptor","volume":"102","author":"Muntasir","year":"2006","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.ejphar.2007.11.056_bib22","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1073\/pnas.050282397","article-title":"5-hydroxytryptamine 2B receptor regulates cell-cycle progression: cross-talk with tyrosine kinase pathways","volume":"97","author":"Nebigil","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejphar.2007.11.056_bib23","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1538-7836.2005.01702.x","article-title":"Inhibition of 5-hydroxytryptamine receptor prevents occlusive thrombus formation on neointima of the rabbit femoral artery","volume":"4","author":"Nishihira","year":"2006","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.ejphar.2007.11.056_bib24","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1161\/01.RES.0000251742.71301.16","article-title":"Activation of platelet function through G protein-coupled receptors","volume":"99","author":"Offermanns","year":"2006","journal-title":"Circ. Res."},{"key":"10.1016\/j.ejphar.2007.11.056_bib25","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0014-2999(02)02654-7","article-title":"Pharmacological profiles of R-96544, the active form of a novel 5-HT2A receptor antagonist R-102444","volume":"457","author":"Ogawa","year":"2002","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2007.11.056_bib26","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/00005344-199808000-00014","article-title":"Vascular and cardiac effects of DV-7028, a selective, 5-HT2-receptor antagonist in rats","volume":"32,","author":"Pawlak","year":"1998","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.ejphar.2007.11.056_bib27","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1136\/bmj.298.6671.424","article-title":"Prevention of atherosclerotic complications: controlled trial of kentanserin","volume":"298","year":"1989","journal-title":"Br. Med. J."},{"key":"10.1016\/j.ejphar.2007.11.056_bib28","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/01.PSY.0000088596.42029.10","article-title":"Increased coronary events in depressed cardiovascular patients: 5-HT2A receptor as missing link","volume":"65","author":"Schins","year":"2003","journal-title":"Psychosom. Med."},{"key":"10.1016\/j.ejphar.2007.11.056_bib29","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/S0735-1097(98)00496-3","article-title":"Improvement of exercise capacity by sarpogrelate as a result of augmented collateral circulation in patients with effort angina","volume":"32","author":"Tanaka","year":"1998","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejphar.2007.11.056_bib30","unstructured":"Teegarden, B.R., Xiong, Y., Strah-Pleynet, S., Jayakumar, H., Dosa, P.I., Feichtinger, K., Casper, M., Lehmann, J., Jones, R.M., Unett, D.J., 2006. 3-Phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto. PCT\/US2005\/041726(WO\/2006\/055734). 5-26-0006. Ref Type: Patent."},{"key":"10.1016\/j.ejphar.2007.11.056_bib31","first-page":"217","article-title":"Vascular effects of ketanserin (R 41 468), a novel antagonist of 5-HT2 serotonergic receptors","volume":"218","author":"Van Nueten","year":"1981","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2007.11.056_bib32","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1161\/01.CIR.100.5.483","article-title":"Serotonin is associated with coronary artery disease and cardiac events","volume":"100","author":"Vikenes","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2007.11.056_bib33","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/0049-3848(96)00030-8","article-title":"Modulation of platelet function and vascular smooth muscle contractile actions by a novel, selective, highly potent 5-HT2 antagonist (SR46349)","volume":"81","author":"Yang","year":"1996","journal-title":"Thromb. Res."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299907013052?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299907013052?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,5]],"date-time":"2019-05-05T10:17:33Z","timestamp":1557051453000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299907013052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5]]},"references-count":33,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2008,5]]}},"alternative-id":["S0014299907013052"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2007.11.056","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2008,5]]}}}